Andrew Danford represents life sciences and technology companies in intellectual property disputes. He has significant experience with biosimilar litigation under Biologics Price Competition and Innovation Act. He has also litigated numerous patent cases through trial and on appeal under the Hatch-Waxman Act, as well as on behalf of innovator pharmaceutical clients in declaratory judgment actions challenging patents held by a competitor. Mr. Danford has also litigated several patent disputes at the trial and appellate levels involving smartphones, microprocessors, telecommunications networks, internet technologies and video compression. 

Mr. Danford's practice encompasses all stages of litigation—from pre-suit investigations through discovery, summary judgment, trial and appeal. His recent trial experience includes several bench and jury trials in federal district courts in Delaware, California, Texas and Wisconsin. He has also appeared in numerous appeals before the US Court of Appeals for the Federal Circuit, as well as in several appeals before the US Supreme Court. In addition, Mr. Danford has experience representing clients in dozens of inter partes review proceedings before the Patent Trial and Appeal Board. He also has experience litigating patent disputes before the US International Trade Commission.

Professional Activities

Mr. Danford has delivered CLE presentations on biosimilars, patent damages, willful infringement, claim construction, and recent developments in patent law at the Federal Circuit and Supreme Court. He is a member of the Boston Intellectual Property American Inn of Court.


  • Represented the plaintiffs in a nine-day bench trial in a Hatch-Waxman litigation concerning patents covering plaintiffs’ blockbuster oral anticoagulant.
  • Represented the patentee in biosimilar litigation concerning a cancer therapy in multiple district court litigations and Federal Circuit appeals, as well as in parallel inter partes review proceedings before the Patent Trial and Appeal Board.
  • Represented the defendant in a 10-day jury trial relating to a microprocessor technology.
  • Briefed many Federal Circuit appeals, including several expedited appeals relating to injunctive relief; multiple appeals from Hatch-Waxman cases concerning antiviral drugs and treatments for sleep disorders; multiple appeals on behalf of defendants challenging infringement, validity, and damages issues; and an appeal involving inventorship dispute over wind turbine technology.
  • Represented the patentee in a 13-day jury trial involving various smartphone technologies.
  • Represented the patentee in a five-day jury damages trial for the infringement of several design and utility patents by competitor's smartphones and tablets.
  • Obtained a covenant not to sue in declaratory judgment action brought by a networking equipment supplier, resulting in summary judgment of exhaustion for the supplier's customers.
  • Represented the patentee in an inventorship dispute involving a COX-2 therapy.
  • Represented the patentee in multi-defendant Hatch-Waxman litigation in the District of Delaware related to proposed generic versions of a drug used to treat abnormal cholesterol levels.


  • Named a "Life Sciences Star" by LMG Life Sciences (2023).
  • Selected by Benchmark Litigation as a "Future Star" in 20222024.
  • Named to Boston Magazine’s inaugural Top Lawyers list in 2021 and 2023 in the area of civil litigation/defense and intellectual property rights.

Insights & News


  • Education

    • JD, Stanford Law School, 2008

      with distinction Order of the Coif
    • SB, Chemistry, Massachusetts Institute of Technology, 2005

      Phi Beta Kappa
  • Admissions

    • Massachusetts

    • New York

    • US Court of Appeals for the Federal Circuit

    • US Court of Appeals for the First Circuit

  • Clerkships

    • The Hon. Sandra L. Lynch, US Court of Appeals for the First Circuit, 2008 - 2009



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.